Microarray-based assays for blood typing and diagnosis of infectious diseases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Scientists at the University of Edinburgh are developing multiplex microarray assays to accelerate routine blood typing and diagnosis of infectious diseases, using Tecan’s LS Reloaded™ laser scanner for automated scanning of both microplates and slides.

 

Dr Colin Campbell, a research fellow at the university, explained: “We are developing microarray technology and assays specifically to improve the understanding and diagnosis of infectious diseases, especially those caused by herpes viruses or HIV. Our LS Reloaded scanner gives us the level of versatility that we need for assay development that other scanners could not provide. For example, the scanner allows a high degree of flexibility with a choice of materials and chip geometries so that we can scan from underneath or above, and can use silicon wafers and non-standard chip sizes.”

 

“We recently developed a microarray-based assay for ABO and Rhesus blood group typing, and are now developing this further to bring all the pre-transfusion testing for other blood groups and infectious diseases together on one microarray,” Dr Campbell continued. “Our ultimate aim is to develop a single microarray-based test that will include all the critical antigens that must be matched for a successful blood transfusion to take place.”

 

To find out more on Tecan’s LS Reloaded scanner, visit www.tecan.com/ls-reloaded

 

For more information about Tecan, please contact:

 

 

 

About Tecan

Tecan (www.tecan.com) is a leading global supplier of laboratory instruments and solutions for the biopharma, forensic and diagnostic industries. The company specializes in the development, production and distribution of automation solutions for life science laboratories. Through its REMP subsidiary (www.remp.com), Tecan is the premier supplier of automated laboratory storage and logistics systems. Tecan's clients include pharmaceutical and biotech companies, university research departments, diagnostic laboratories and companies as well as forensics laboratories. Founded in Switzerland in 1980, the company has production, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2007, Tecan achieved sales of CHF 414.4 million (USD 345.3 million; EUR 252.7 million). Registered shares of the Tecan Group are traded on the SWX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Valor: 1210019).